KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analogue with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.
Achaporn Yipsirimetee, Pornpawee Chiewpoo, Rupam Tripura, Dysoley Lek, Nicholas Day, Arjen M. Dondorp, Sasithon Pukrittayakamee, Sir Nicholas White, Kesinee Chotivanich
Tran Tinh Hien, Sir Nicholas White, Thuy-Nhien Nguyen, Nhu Thi Hoa, Phung Duc Thuan, Joel Tärning, François Nosten, Baldur Magnusson, Jay Prakash Jain, Kamal Hamed
Sir Nicholas White, Tran Thanh Duong, Chirapong Uthaisin, François Nosten, Aung Pyae Phyo, Borimas Hanboonkunupakarn, Sasithon Pukrittayakamee, Podjanee Jittamala, Kittiphum Chuthasmit, Ming S. Cheung, Yiyan Feng, Ruobing Li, Baldur Magnusson, Marc Sultan, Daniela Wieser, Xiaolei Xun, Rong Zhao, Thierry T. Diagana, Peter Pertel, F. Joel Leong
Achaporn Yipsirimetee, Phornpimon Tipthara, Borimas Hanboonkunupakarn, Rupam Tripura, Dysoley Lek, Krittikorn Kümpornsin, Lee M, Jetsumon Sattabongkot, Arjen M. Dondorp, Sir Nicholas White, Kevin C. Kobylinski, Joel Tärning, Kesinee Chotivanich
Discussion(0)
No comments yet. Be the first to comment.